Blood Cancer Care

UNIVERSITY OF CINCINNATI CANCER CENTER ANNOUNCING THE NEW BLOOD CANCER HEALING CENTER

The future of cancer care is happening here in the only blood cancer center in the nation where all patients can access all their care in one building.

Cancer patients, survivors, researchers, and clinicians can now come together to advance healing, thanks to Frances and Craig Lindner and other generous donors from across our community.

The future of cancer care is better outcomes.

Cancer patients see direct benefits from the new standards being set at the Blood Cancer Healing Center, including:

• Advanced and unique treatment options
• Higher survival rates–up to 33% higher than the national average for acute myeloid leukemia (AML)
• Lower recurrence rates
• Better quality of life
• Calming experience for inpatients and outpatients
• Easy coordination and access
• More time spent at home

Better outcomes and more second chances are possible because of the breakthrough treatments developed here. The Blood Cancer Healing Center houses the only adult academic health system phase 1 (first-in-human) clinical trials in the region, giving patients access to new therapies.

Cancer treatments, like chemotherapy, can result in short and long-term side effects. That’s why we prioritize whole-person wellness support to alleviate symptoms during treatment, minimize long-term effects, and achieve optimal quality of life through:

• Symptom management from the region’s largest supportive services program.
• The region's first and only oncology primary care program.
• Lifestyle medicine care plans from the Osher Center for Integrative Health at UC, one of only 11 Osher Centers in the world collaborating with institutions like Harvard, Vanderbilt, and more.

Our world-class team is redefining what’s possible.

Dr. John Byrd has assembled an incomparable women-led research team and exceptional care teams leading the future of blood cancer.

Dr. Byrd is the top-rated expert in leukemia, lymphocytic and chronic B-cell cancers (CLL). The revolutionary targeted treatment he and his team developed for CLL has drastically prolonged remission and increased patient life expectancy.

These clinicians lead Beat AML, the first clinical trial for blood cancer patients that centers on collaboration across hospital systems.